ArticleResearch and practice in thrombosis and haemostasis2025

Rituximab-first versus eltrombopag monotherapy in pediatric persistent/chronic immune refractory thrombocytopenia after first-line therapy: a prospective multicenter cohort study.

Jingyao Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.